ASCO 2022
In-depth coverage of the ASCO 2022 Annual Meeting
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Prostate cancer highlights from ASCO 2022 are discussed, including the ENZAMET trial design and TheraP trial data.
Highlights from ASCO 2022, including the role of doublet therapy (ADT combined with a novel oral antiandrogen drug).
The findings are notable for a patient population that has limited treatment options.
Cell-free DNA (cfDNA) methylation may be used to predict treatment response in patients with muscle-invasive bladder cancer.
The TheraP ANZUP 1603 trial showed both options were suitable for men with mCRPC.
The treatment was also compared to an active comparator of non-steroidal anti-androgen.
Researchers hypothesized that switch maintenance therapy with the TKI would improve outcomes for the metastatic disease.
The data were from a randomized phase-2 study assessing new treatment combinations in patients with advanced clear cell RCC.
The findings could lead to improved outcomes in men with PSMA PET-positive mCRPC.
Researchers found it had clinical efficacy regardless of patients' prior treatment or standard of care chosen.
The results mean that progression-free survival endpoints could be used to expediate phase-3 clinical trials.
The rate of relapses occurring 2 or 5 years after disease-free survival is low among testicular cancer patients, study finds.
The association between health-related quality of life and clinical outcomes was identified in the CheckMate 214 study.
There were previously no data comparing second-generation ARIs with first-generation ARIs.
Advertisement
Advertisement
